Skip to main content

Advertisement

Table 1 Total number of samples successfully amplified for pfmdr1 copy number and sequenced for pfmdr1 and pfk13 from therapeutic efficacy monitoring in Angola, 2015

From: Prevalence of molecular markers of artemisinin and lumefantrine resistance among patients with uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2015

  Benguela Lunda Sul Zaire Total
Pretreatment
 pfk13 sequence 188/188 (100%) 82/82 (100%) 199/199 (100%) 469/469 (100%)
 pfmdr1 copy number 195/199 (98%) 99/101 (98%) 203/206 (99%) 497/506 (98%)
 pfmdr1 sequence 194/198 (97%) 96/101 (95%) 201/207 (97%) 491/506 (96%)
Day of late treatment failure
 pfk13 sequence 15/15 (100%) 0 35/35 (100%) 50/50 (100%)
 pfmdr1 copy number 15/15 (100%) 0 31/34 (91%) 46/49 (94%)
 pfmdr1 sequence 15/15 (100%) 0 35/35 (100%) 50/50 (100%)
Total samples
 pfk13 sequence 203/203 (100%) 82/82 (100%) 234/234 (100%) 519/519 (100%)
 pfmdr1 copy number 210/214 (98%) 99/101 (98%) 234/240 (98%) 543/555 (98%)
 pfmdr1 sequence 209/213 (97%) 96/101 (95%) 236/242 (97%) 541/556 (97%)